aTyr Pharma
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10240 Sorrento Valley Rd Ste 300, San Di...Phone Number
(858) 731-8389Website
www.atyrpharma.comRevenue
<$5 MillionStock Symbol
ATYRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About aTyr Pharma
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases.Explore more
aTyr Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is aTyr Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if aTyr Pharma had a recent Job posting/layoffs
aTyr Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when aTyr Pharma launches new products
Check out if aTyr Pharma is spiking on competitors!
Earning: See what the market has to say on aTyr Pharma recently announced quarterly report
Funding: Get notified immidiatlly once aTyr Pharma has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at aTyr Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if aTyr Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined aTyr Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to aTyr Pharma
Compare insights from companies similar to aTyr Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
aTyr Pharma
<$5M
51-200
Public
$340.3M
2005
MA
Melissa AshlockVice President, External Scientific Alliances & Human Genetics
$17.3M
51-200
Private
$71M
2014
GR
Guy RachmuthSenior Vice President, Global Head of Strategic BD and Partnerships. Chief Business Officer
Company Profile Activity
Activity Insights
aTyr Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
aTyr Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about aTyr Pharma.
aTyr Pharma financials insights
Gather financial insights about aTyr Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series B
$10.5M
2010
Series C
$23M
2013
Debt
$10M
Series D
$49M
2015
Series E
$76M
Stock Offering
$86M
2016
Debt
$20M
2017
Share Placement
$45.8M
2020
Share Placement
$20M
aTyr Pharma Tech Stack
A closer look at the technologies used by aTyr Pharma
Most Recent Scoops
Person-Based
Compliance
Pain Point
Pain Point, Lawsuits, Legal Affairs, Pharmaceuticals, Finance
Event
presented baseline demographics from its current Phase 3 pulmonary sarcoidosis study at ATS in San Francisco. The data was largely as expected, with baseline characteristics similar to those observed in the Phase 2 trial.
Medical Research, Pharmaceuticals, Clinical Operations
Project
reported that its recent epidemiology study shows the steroid-dependent sarcoidosis population in the US is larger than initially estimated, at about 150,000-160,000 patients. This represents a 30-60% increase from initial estimates, potentially expanding the market opportunity.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals, Clinical Operations
aTyr Pharma News & Media
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate UpdateaTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma to Participate in Upcoming Investor ConferencesaTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting. President and CEO Dr. Sanjay Shukla said the meeting, held in mid-April with official minu
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding aTyr Pharma
Sign Up For FreeTo access detailed company insights
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual proper... Read More
